tuneTypical Dose
2,000 MG to 20,000 MG
Amino Acid
BCAA
Leucine, Isoleucine, Valine
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Hours to days for recovery biomarkers. 8-12 weeks for body-composition/training interaction outcomes.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Branched-chain amino acids are leucine, isoleucine, and valine, essential amino acids involved in muscle signaling. They are used to support training recovery when protein intake is low.
Leucine contributes to muscle protein synthesis signaling, but benefits are most apparent when total protein intake is insufficient. Studies show modest reductions in soreness and perceived exertion in some athletes. Minority findings include reduced central fatigue during endurance exercise, with mixed results. Complete protein generally produces stronger and more consistent outcomes.
BCAA supplementation increases availability of essential branched-chain amino acids for anabolic and recovery signaling, with potential context-specific effects under low-protein or high-damage conditions.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- In older adults with sarcopenia, BCAA + resistance training produced a small improvement in skeletal muscle index (SMD 0.337, 95% CI 0.035-0.639).
- BCAA protocols more consistently reduce post-exercise CK than they improve performance outcomes.
Secondary Outcomes
- A small pilot in untrained recreational cyclists showed shorter time-to-completion with acute BCAA dosing, but with mixed neuromuscular signals and higher heart rate.
- Evidence for routine fatigue prevention in general athletes remains inconsistent.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- Renal impairment
- Severe hepatic disease
- MSUD
- Unstable comorbid disease
Side effects
- Nausea
- Stomach discomfort
- Fatigue
Interactions
- Total amino-acid stack overlap
- Insulin-related regimens
- High-nitrogen co-supplementation
Avoid if
- Active severe renal/hepatic disease
- Complex polypharmacy without clinician support
- Unverified anti-doping-sensitive competition without list check
Evidence
Study-level References
bcaa-SRC-001Meta-analysis of 12 RCTs
Sourceopen_in_newLi H et al. Arch Gerontol Geriatr. 2026 Feb. doi: 10.1016/j.archger.2025.106063; PMID: 41202431.
Population: Older adults with sarcopenia (n=459)
Dose protocol: BCAA-rich supplement plus resistance training
Key findings: SMI improved (SMD 0.337, 95% CI 0.035-0.639, p=0.029). No meaningful effects on hand-grip strength, chair-stand, SPPB, walking speed, knee extension strength, or lean/fat mass.
Notes: Moderate. Substantial protocol heterogeneity and co-intervention differences.
Paper content
SMI improved (SMD 0.337; 95% CI 0.035–0.639; p=0.029). No meaningful effects on hand-grip strength, chair-stand, SPPB, walking speed, knee extension strength, or lean/fat mass.
bcaa-SRC-002Meta-analysis of RCTs (exercise-induced muscle damage)
Sourceopen_in_newRahimi MH et al. Nutrition. 2017. doi: 10.1016/j.nut.2017.05.005; PMID: 28870476.
Population: 8 controlled trials, mixed exercised populations
Dose protocol: Oral BCAA strategies across trials, compared with placebo recovery
Key findings: Creatine kinase reduced at <24h (MD -71.55 U/L) and 24h (MD -145.04 U/L). No significant pooled effect on soreness or LDH reported.
Notes: Moderate. Older evidence base, variable outcomes, small studies.
Paper content
Creatine kinase reduced at <24h (MD -71.55 U/L) and 24h (MD -145.04 U/L); no significant pooled effect on soreness or LDH reported.
bcaa-SRC-003Systematic review
Sourceopen_in_newFouré A et al. Nutrients. 2017. doi: 10.3390/nu9101047; PMID: 28934166.
Population: 11 studies of BCAA supplementation in exercise-induced muscle damage
Dose protocol: Trial strategies by dose/frequency/duration. Strongest signals with higher daily intake and ≥10 days where damage is low-to-moderate.
Key findings: BCAA use can reduce damage biomarkers under selected protocols. Functional outcomes depend heavily on protocol and damage severity.
Notes: Moderate. Inclusion limited by inconsistent biomarkers and potential publication bias in older exercise literature.
Paper content
BCAA use can reduce damage biomarkers under selected protocols; functional outcomes depend heavily on protocol and damage severity.
bcaa-SRC-004Systematic review
Sourceopen_in_newMartinho DV et al. Nutrients. 2022. doi: 10.3390/nu14194002; PMID: 36235655. (Systematic review including athletes)
Population: 24 studies in athletic/physically active adults
Dose protocol: Heterogeneous oral BCAA products and doses
Key findings: Aggregate anabolic signaling effects are plausible, but performance/body-composition gains are generally negligible/heterogeneous.
Notes: Moderate-to-high due protocol heterogeneity and inconsistent protein-intake control.
Paper content
Aggregate anabolic signaling effects are plausible, but performance/body-composition gains are generally negligible/heterogeneous.
bcaa-SRC-005Regulatory list
Sourceopen_in_newWorld Anti-Doping Agency. The Prohibited List (official guideline URL).
Population: Current competitive anti-doping policy framework
Dose protocol: N/A
Key findings: No dedicated BCAA prohibition category is published as a banned substance class.
Notes: Low governance certainty, but athlete-level contamination and product-adulteration risk remain.
Paper content
No dedicated BCAA prohibition category is published as a banned substance class.
bcaa-SRC-006Systematic review and meta-analysis with meta-regression
Sourceopen_in_newSalem A, Ben Maaoui K, Jahrami H, et al. Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression. Sports Med Open. 2024;10(1):42. doi:10.1186/s40798-024-00686-9. PMID:38625669.
Population: Healthy active participants performing resistance or endurance exercise across 18 RCTs.
Dose protocol: Meta-analysis of 18 RCTs examining BCAA supplementation versus placebo/control in exercising individuals.
Key findings: BCAAs significantly reduced CK immediately (g = -0.44, P = 0.006) and at 72h (g = -0.99, P = 0.002). DOMS reduced at 24-96h with largest effect at 72h (g = -1.82). LDH not significantly affected.
Notes: The most comprehensive meta-analysis to date on BCAAs and exercise-induced muscle damage. Strengthens the CK and soreness signal while confirming no LDH effect.
Paper content
This meta-analysis of 18 RCTs examined BCAA supplementation for exercise-induced muscle damage. BCAAs significantly reduced creatine kinase immediately (g = -0.44, P = 0.006) and at 72 hours post-exercise (g = -0.99, P = 0.002). Delayed onset muscle soreness was significantly lower at 24 through 96 hours, with the largest effect at 72 hours (g = -1.82). LDH was not significantly affected. Longer supplementation periods yielded greater benefits. The findings support BCAAs for reducing muscle damage biomarkers and soreness but not for all damage markers.
bcaa-SRC-007Randomized, double-blind crossover trial
Sourceopen_in_newMarrone G, Di Lauro M, Cornali K, et al. The Combined Use of Hydroxymethylbutyrate and Branched-Chain Amino Acids to Counteract Uremic Sarcopenia. Nutrients. 2026;18(3):483. doi:10.3390/nu18030483. PMID:41683304.
Population: Adult hemodialysis patients with uremic sarcopenia.
Dose protocol: BCAAs plus HMB plus zinc at 10 g/day for 12 weeks in 24 hemodialysis patients, crossover design with 8-week washout.
Key findings: Increased quadriceps muscle thickness and fat-free mass, reduced oxidative stress and inflammatory markers, improved quality-of-life domains. No short-term functional performance changes.
Notes: Small clinical population (hemodialysis). Combined intervention (HMB + zinc) limits BCAA-specific attribution. Supports BCAAs in disease-related sarcopenia.
Paper content
This crossover RCT tested BCAAs combined with HMB and zinc (10 g/day for 12 weeks) in 24 hemodialysis patients. The supplement increased quadriceps muscle thickness and fat-free mass, reduced oxidative stress and inflammatory markers, and improved quality-of-life domains (energy/fatigue and general health) without short-term functional performance changes. The study supports targeted BCAA-based supplementation for muscle preservation in chronic kidney disease.